Pembrolizumab,Lenvatinib,Regorafenib,trifluridine,Tipiracil,Botensilimab,Balstilimab
Merck,Eisai,Bayer,Taiho pharma,Pfizer,Agenus
['balstilimab', 'botensilimab', 'agenus']
 it seems that the numbers reported by agenus re: their botensilimab/balstilimab combo showed clear benefit over soc along with manageable aes. and the responses appear to be durable.
Part of the silent majority